News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Candela (CLZR) Achieves Approval to Market Its Vbeam(R) Lasers in Japan

7/19/2010 11:19:29 AM

WAYLAND, MA--(Marketwire - July 19, 2010) -

Candela Corporation, a subsidiary of Syneron Medical Ltd. (NASDAQ: ELOS), today announced that it has received registration approval from the Japanese Ministry of Health, Labour and Welfare to market its Vbeam® long pulsed dye laser system in Japan for the treatment of vascular conditions. The Candela Vbeam is the first and only long pulsed dye laser system approved for use in Japan.

"We are honored that the Vbeam long pulsed dye laser system has been approved for use in Japan," said Lou Scafuri, Chief Executive Officer of Syneron. "This marks a significant milestone in our global distribution as physicians and patients in Japan will now have full access to the gold standard treatments that Vbeam offers."

The approval will also help facilitate health insurance payments to physicians and patients allowing for certain medical conditions to be reimbursed. "This helps physicians and patients alike, offering a new and improved treatment option for high demand vascular lesion procedures, such as port wine stain and hemangiomas," said Dr. Taro Kono, Chief of Laser Section, Department of Plastic and Reconstructive Surgery, Tokyo Women's Medical University.

Globally recognized within the medical community as the recommended choice in targeting vascular conditions, Vbeam long pulsed dye laser represents an unparalleled 25-year track record of science, safety, reliability and efficacy for in demand procedures such as port wine stain, hemangioma, rosacea and skin rejuvenation. "Our patients who suffer from cutaneous vascular lesions will be pleased to have access to Vbeam," said Prof. Muneo Miyasaka, Department of Plastic and Reconstructive Surgery, Tokai University. "The Japanese Society of Plastic and Reconstructive Surgery recognizes the critical need for this system and fully supports the approval of the Vbeam long pulsed dye laser."

To learn more about the Candela Vbeam® family of pulsed dye lasers, including before and after photos, visit

About Vbeam
The Vbeam family of pulsed dye lasers represents an unparalleled 25-year track record in safety, reliability and efficacy. Vbeam offers a wide range of solutions from vascular lesions such as rosacea, facial and leg veins, hemangioma and port wine stains to skin rejuvenation such as sun and age spots, fine lines and wrinkles, stretch marks and warts. Vbeam treatments are comfortable and generally do not require any numbing creams or messy gels during treatment due to Candela's proprietary Dynamic Cooling Device® which emits an evaporative cooling spray before each laser pulse increasing safety and patient comfort. Vbeam technology enables uniform and consistent delivery of energy to underlying blood vessels, providing gentle, consistent treatment results that eliminate patient downtime and prevent bruising.

To learn more about the Vbeam® family of pulsed dye lasers, including the latest clinical data and before and after photos, visit

About Syneron Medical Ltd.
Candela Corporation is a wholly-owned subsidiary of Syneron Medical Ltd. -- a company dedicated to real technology, real science and real results -- the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets, services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan and Hong Kong and distributors worldwide.

Additional information can be found at

Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.

Digg this    Bookmark with    Add to Newsvine


Read at

comments powered by Disqus